Every 10-Q that Tonix Pharmaceut (TNXP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TNXP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNXP filings page.
Tonix Pharmaceuticals Holding Corp. reported strong early commercialization of its CNS portfolio but continued heavy losses for the quarter ended June 30, 2026. Net product revenue was $13.5 million for the quarter and $20.4 million for the first half of 2026, up sharply from 2025, driven mainly by the U.S. launch of TONMYA for fibromyalgia and migraine products Zembrace SymTouch and Tosymra.
Operating expenses increased substantially as the company scaled commercial and R&D activities. For the first half of 2026, research and development expense was $37.6 million and selling, general and administrative expense was $64.6 million, leading to a net loss of $80.7 million for the six-month period. Cash used in operating activities was $84.6 million.
Tonix ended June 30, 2026 with $176.2 million in cash and cash equivalents, total assets of $254.1 million and working capital of approximately $172.6 million, supported by $53.6 million of ATM equity proceeds in the first half. Management expects existing cash plus subsequent equity raises to fund operations into early second quarter 2027, but not for 12 months from the financial statement issuance date, and disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern. The company continues to advance a broad pipeline across CNS, infectious disease, immunology and rare diseases, including Phase 2 and preclinical programs.
Tonix Pharmaceuticals reported sharply higher Q1 2026 net product revenue of $6.9 million, up from $2.4 million a year earlier, driven mainly by the launch of fibromyalgia drug TONMYA and growth in migraine products Zembrace SymTouch and Tosymra.
Despite this growth, Tonix posted a larger net loss of $40.2 million versus $16.8 million in Q1 2025 as research and development spending rose to $18.2 million and selling, general and administrative costs increased to $28.6 million, reflecting commercialization and pipeline investments.
The company ended March 31, 2026 with $185.5 million in cash and cash equivalents and working capital of about $177.5 million, but disclosed that these resources, including additional equity raised in Q2 2026, are expected to fund operations only into early second quarter 2027, leading to a stated substantial doubt about its ability to continue as a going concern without new financing.
Tonix Pharmaceuticals (TNXP) reported Q3 2025 results. Product revenue was $3.29 million, up from $2.82 million a year ago. Operating loss was $33.07 million and net loss to common stockholders was $32.01 million, or $3.59 per share. Selling, general and administrative expenses were $25.70 million versus $7.71 million last year, and research and development was $9.29 million versus $9.11 million.
As of September 30, 2025, cash and cash equivalents were $190.06 million and total assets were $252.44 million. The company eliminated its term loan, reducing debt to zero from $4.67 million at December 31, 2024. Year‑to‑date, net cash provided by financing activities was $155.39 million, including $170.99 million of proceeds from sales of common stock and warrants.
Tonix received FDA approval for Tonmya in August 2025 and expects a U.S. launch before the end of November 2025. Management states current cash plus $34.7 million of Q4 2025 equity proceeds are expected to fund operations into the first quarter of 2027. Shares outstanding were 11,776,542 as of November 10, 2025.
Tonix Pharmaceuticals (TNXP) reported cash and cash equivalents of $125.3 million, total assets of $187.4 million and stockholders' equity of $168.0 million at June 30, 2025, with working capital of approximately $124.5 million and an accumulated deficit of about $775.8 million. Product revenue totaled $2.0 million for the quarter (down from $2.2 million a year earlier) and $4.4 million for the six months (down from $4.7 million). The company reported a net loss of $28.3 million for the quarter and $45.1 million for the six months, driven by $16.2 million of selling, general and administrative expense and elevated R&D spending.
The company highlighted regulatory and pipeline progress: a PDUFA goal date of August 15, 2025 for TNX-102 SL with no FDA Advisory Committee meeting required and Fast Track designation; first patient enrolled in an ASD/ASR study in May 2025; positive Phase 1 topline for TNX-1500 supporting a Phase 2 kidney transplant program; and a DTRA contract for up to $34.1 million for TNX-4200 with $2.0 million of grant income recognized year-to-date. Management disclosed substantial doubt about going concern despite noting cash plus subsequent equity proceeds intended to fund operations into the third quarter of 2026.